Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

December 9th 2021

Mental Health Distress Impacting Cancer Patients, Says New Cardinal Health Survey of Oncologists

More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes.

December 8th 2021

Flatiron Health Leverages Expertise With Real-World Data to Examine Cancer Care Disparities

Mary Caffrey

November 23rd 2021

Achieving Equitable Breast Cancer Care: Clinical Trials, Mental Health, and Digital Therapeutics

Matthew Gavidia

Discussions regarding health equity and access to care have long been implicated in breast cancer. Here, key opinion leaders discuss the latest progress in clinical trial access, digital therapeutics, and other efforts that aim to ameliorate these care gaps.

November 22nd 2021

Dr Karen van Caulil: End of Oncology Care Model Could Leave Gap in Comprehensive Care

Hayden E. Klein

Karen L. van Caulil, PhD, president and CEO of Florida Alliance for Healthcare Value, discusses the potential gap in care that may occur with the end of the Oncology Care Model.

November 22nd 2021

With No Replacement for OCM on Horizon, Oncology Practices Ask: What Now?

Gianna Melillo

The announcement of a "strategic refresh" for payment models under the Center for Medicare and Medicaid Innovation offered no details on what practices should expect when the Oncology Care Model (OCM) expires in 2022.

clipart images of an apple, pill bottle, healthcare forms, doctors, hand holding a heart, piggy bank with a calculator, and a stack of money

November 20th 2021

US Oncology Network, Tennessee Oncology Tout Medicare OCM Savings

Skylar Jeremias

A report from the Centers for Medicare and Medicaid Innovation confirmed that practices within the US Oncology Network and Tennessee Oncology participating in the Oncology Care Model (OCM) program have contributed significant savings to the agency.

November 20th 2021

Dr Funmi Olopade: Breast Cancer Screening Is Not One Size Fits All

Hayden E. Klein

Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains how different populations are at different risk for breast cancer and the importance of informed screening.

November 7th 2021

Contributor: Don’t Delay—Why Now Is the Time to Reengage Patients in Routine Cancer Screenings

Matt Dickson

Ignoring life-threatening, non–COVID-19 conditions for too long can turn one health crisis into another. Now is the time to resume cancer screenings, like mammograms and colonoscopies, because early detection can be lifesaving.

October 3rd 2021

Consolidative Radiation Therapy Improves Progression-Free Survival in DLBCL

Deanna Ferreri, PhD

This new study shows that consolidative radiation therapy may be of benefit to persons with diffuse large B-cell lymphoma, both bulky and nonbulky disease.

October 1st 2021

Dr Marcus Neubauer Outlines the Benefits of the OCM and the Potential Successor Model

The Oncology Care Model (OCM) was a great program that led to practice transformation and improved patient care, but there needs to be a way to address the high cost of cancer therapies, said Marcus Neubauer, MD, chief medical officer of the US Oncology Network.

Elizabeth Kwo, MD, MBA, MPH, deputy chief clinical officer at Anthem BCBS, a

September 29th 2021

Dr Elizabeth Kwo on Using Predictive Analytics to Curb Avoidable Hospitalizations During Cancer Therapy

Anemia, fevers, dehydration, and other side effects from cancer treatment are all candidates for targeting with predictive analytics in an effort to care for patients are home instead of the hospital, said Elizabeth Kwo, MD, MBA, MPH, the deputy chief clinical officer at Anthem BCBS, and a speaker at the 10th anniversary of Patient-Centered Oncology Care® conference.

Advances in Understanding of DLBCL Offer Prognostic and Theraptic Value

September 26th 2021

Surface Proteins in DLBCL Offer Therapeutic Targets

Deana Ferreri, PhD

Increasing knowledge of mutations and signaling proteins in diffuse large B-cell lymphoma (DLBCL) offer prognostic and therapeutic advantages, according to a review of recent findings.

September 19th 2021

Frontline Cemiplimab With Chemo Offers Benefits in Advanced NSCLC Regardless of PD-L1 Status

Mary Caffrey

Sanofi and Regeneron had previously announced an overall survival advantage of 29% over chemotherapy alone; the combination also had a progression-free survival benefit of 46%.

September 19th 2021

In HER2+ MBC, Trastuzumab Deruxtecan Slashes Risk of Disease Progression, Death by 72% vs T-DM1

Mary Caffrey

The prespecified analysis of DESTINY-Breast03 opened a Presidential Symposium September 18, during the European Society of Medical Oncology (ESMO) 2021 Virtual Congress, with the study’s lead author predicting a new standard of care and a commentator calling the results “startling.”

Young woman undergoing chemotherapy with physician.

September 14th 2021

Spotlighting Social, Emotional Needs in Underserved Populations With Cancer

Matthew Gavidia

Psychological and emotional needs specific to populations with cancer are often overlooked in clinical research, including those of adolescents, young adults, immigrants, and people of lower socioeconomic status.

September 8th 2021

Dr Gary Lyman: Pandemic Barriers Led to More Late-Stage Cancer Presentations

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how doctors are managing patients who present with later-stage cancers as a result of barriers to screening measures imposed by the pandemic.

September 5th 2021

Study: PET/CT Scans Predict for Response in Salvage-Stage DLBCL

Tony Hagen

For patients with diffuse large B-cell lymphoma (DLBCL), PET/CT scans conducted in the first cycle of salvage therapy can predict for response, according to a study.

August 29th 2021

A Review of Standard of Care in DLBCL

Tony Hagen

A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care.

August 16th 2021

Genomic Complexity Linked With Poor Outcomes in DLBCL

Jared Kaltwasser

A new report could eventually help investigators better understand which patients with diffuse large B-cell lymphoma (DLBCL) are most likely to respond to certain therapies.

August 13th 2021

High-Dose Methotrexate Effective in Preventing Isolated CNS Relapse in Diffuse Large B-Cell Lymphoma

Matthew Gavidia

Risk of isolated central nervous system (CNS) involvement was found to be significantly lower in patients with diffuse large B-cell lymphoma who received high-dose methotrexate vs RCHOP chemotherapy, although risk of concomitant CNS-systemic relapse rates were similar between both groups.

August 11th 2021

Meta-Analysis Finds CIT Regimens Associated With Improved Survival, Safety Outcomes in NSCLC

Jaime Rosenberg

Due to the lack of head-to-head trials comparing chemoimmunotherapy regimens with chemotherapy alone as first-line treatment for non-small cell lung cancer, researchers conducted a network meta-analysis of 17 randomized controlled trials of patients with the cancer.

August 1st 2021

An Inside Look at Disparities in Lung Cancer Care for At-Risk Populations

Matthew Gavidia

On World Lung Cancer Day, we explore current guidelines for lung cancer screening in the United States, implications of the COVID-19 pandemic, and disparities in mortality and access to care by race and socioeconomic status.

July 30th 2021

Long-term Survival Trends Among AYAs With the Highest Mortality Cancer Types

Laura Joszt, MA

Long-term survival trends among adolescents and young adults (AYAs) with the cancer types with the highest mortality highlight areas where additional research is needed.

July 23rd 2021

Addressing Financial Toxicity With Patients and Health Systems

Laura Joszt, MA

Speakers at the Advanced Topics for Oncology Pharmacy Professionals Summit discussed financial toxicity in health care, how it particularly impacts patients with cancer, and how to address the issue with patients and the health system.

July 20th 2021

CMS Seeks Changes to Radiation Oncology Model; ASTRO Responds

Mary Caffrey

Due to unprecedented disruption and missed screenings during the pandemic, efforts to implement a 5-year performance period under the Radiation Oncology Model were extended twice.

Todd Schlesinger, MD, FAAD, Dermatology and Laser Center of Charleston, Clinical Research Center of the Carolinas

July 16th 2021

Dr Todd Schlesinger: Surgical Decisions for Skin Cancer Are Multimodal

Maggie L. Shaw

The characteristics of the tumor and the presence of surgical fatigue can help determine patients’ candidacy for skin cancer surgery, explained Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

July 13th 2021

ASCO, COA Release Updated Standards for Oncology Medical Home

Mary Caffrey

The new standards come as community oncology practices await word on the future of the oncology care model, which will expire in 2022.

July 8th 2021

Obesity, Disparities, and Treatment Advancements Shape US Cancer Trends

Gianna Melillo

New data underscore how obesity, racial disparities and recent treatment advancements have impacted cancer mortality and incidence rates.

July 1st 2021

Next-Generation Oncology APMs Need More Planning to Succeed

Maggie L. Shaw

Originally set to expire on June 30, 2021, the Oncology Care Model was extended for an additional year in light of the COVID-19 pandemic.

June 21st 2021

Weidner et al, Appendices

Susan Weidner, MBA, MS Michael Diaz, MD Cass Schaedig Lucio Gordan, MD

Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology

...

15 16 17 18 19 20 21 22 23

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions